WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Lunet zorg
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Industrial Impact, Medical
Businesswire | May 05, 2023
Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications to assist in diagnosing cancer, announced it is working with Visiopharm, an artificial intelligence (AI)-driven precision pathology software provider, to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, a...
Research
Quantgene | June 08, 2021
Quantgene, biotechnology, cloud, and AI company located in Santa Monica, CA, and Berlin, Germany, has demonstrated the most exact gene sequencing yet published in the industry, as shown in the February edition of GENES, a major scientific journal in medical genomics. "Precision Genomics is revolutionizing medicine, but it is being hampered by a lack of rapid, accurate, and easily accessible technology," said Jo Bhakdi, CEO of Quantgene. "Today, the protection of hum...
Medical
Pfizer | January 15, 2021
Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...
Cell and Gene Therapy
Clearmind Medicine Inc. | September 26, 2022
Clearmind Medicine Inc. a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announces that it will be consolidating all of the issued and outstanding common shares of the Company on the basis of one (1) post consolidation Common Share for each thirty (30) pre consolidation Common Shares. The Corporation's board of directors set September 30, 2022 as the effective date of the Consolidation...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE